Beyond Air Prices $10.2M At-the-Market Private Placement, with Potential Upside to $30.1M if Warrants Are Exercised
XAIR is trading near its 52-week low of $5.1 (7.8% above the low).
Summary
Beyond Air, Inc. announced a private placement expected to generate $10.2 million in upfront gross proceeds, with the potential for up to $30.1 million if all warrants are exercised. Priced at-the-market and including participation from the CEO and CFO, the financing provides critical capital as the company faces a going concern warning and a Nasdaq delisting deadline.
Key Events · Financing and Capital Events · XAIR
-
Private Placement Announced
On July 29, 2026, Beyond Air entered into a securities purchase agreement to sell 167,011 shares of common stock, pre-funded warrants for 1,638,835 shares, and Series A and B warrants each for 1,805,846 shares in a private placement.
-
Upfront Proceeds of $10.2M
The transaction is expected to generate approximately $10.2 million in gross proceeds at closing, before placement agent fees and expenses. If all warrants are exercised for cash, total proceeds could reach $30.1 million.
-
At-the-Market Pricing
Under Nasdaq rules, the combined purchase price per share and accompanying warrants is $5.66 for institutional investors and $5.76 for participating directors and officers, priced at-the-market. The pre-funded warrant price is $5.6599.
-
Insider Participation
CEO Robert Goodman and CFO Daniel Moorhead are participating in the private placement on the same terms as institutional investors, except for a slightly higher per-share price of $5.76, and are not purchasing pre-funded warrants.
Analysis · XAIR · Industrial Applications And Services
Facing a going concern warning and a Nasdaq delisting deadline, micro-cap medical device company Beyond Air has secured $10.2 million in immediate gross proceeds through a private placement of common stock and warrants. The deal is priced at-the-market under Nasdaq rules: institutional investors pay $5.66 per share, while insiders including the CEO and CFO pay $5.76. The financing also includes pre-funded warrants and two series of common warrants that could bring in an additional $19.9 million if fully exercised for cash, though exercise is not guaranteed. This capital is critical for extending the company's cash runway and funding the planned commercial launch of its second-generation LungFit PH device, pending FDA approval. Senior executives are participating alongside institutional investors, signaling alignment, but the dilutive impact is significant given the company's small market capitalization. Placement agents will receive a 7% cash fee on gross proceeds, and the company has committed to file a resale registration statement within 15 days of closing, which will create an overhang on the stock.
At the time of this filing, XAIR was trading at $5.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $5.10 to $95.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.